Experimental Nephrology and Genetics: Research Article

Vaisbich M.H. · Messa A.C.H.L. · Rangel-Santos A.C. · Ferreira J.C.O.A. · Nunes F.A.M.F. · Watanabe A.

Author affiliations

Instituto da Criança do Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: May 07, 2022
Accepted: November 28, 2022
Published online: March 07, 2023

Number of Print Pages: 18
Number of Figures: 3
Number of Tables: 3

ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)

For additional information: https://www.karger.com/NEF

Abstract

Background: Genetic testing is recommended for accurate diagnosis of Bartter syndrome (BS) and serves as a basis for implementing specific target therapies. However, populations other than Europeans and North Americans are underrepresented in most databases and there are uncertainties in the genotype-phenotype correlation. We studied Brazilian BS patients, an admixed population with diverse ancestry. Methods: We evaluated the clinical and mutational profile of this cohort and performed a systematic review of BS mutations from worldwide cohorts. Results: Twenty-two patients were included; Gitelman syndrome was diagnosed in 2 siblings with antenatal BS and congenital chloride diarrhea in 1 girl. BS was confirmed in 19 patients: BS type 1 in 1 boy (antenatal BS); BS type 4a in 1 girl and BS type 4b in 1 girl, both of them with antenatal BS and neurosensorial deafness; BS type 3 (CLCNKB mutations): 16 cases. The deletion of the entire CLCNKB (1–20 del) was the most frequent variant. Patients carrying the 1–20 del presented earlier manifestations than those with other CLCNKB-mutations and the presence of homozygous 1–20 del was correlated with progressive chronic kidney disease. The prevalence of the 1–20 del in this BS Brazilian cohort was similar to that of Chinese cohorts and individuals of African and Middle Eastern descent from other cohorts. Conclusion: This study expands the genetic spectrum of BS patients with different ethnics, reveals some genotype/phenotype correlations, compares the findings with other cohorts, and provides a systematic review of the literature on the distribution of BS-related variants worldwide.

© 2023 S. Karger AG, Basel

References Bartter FC, Pronove P, Gill JR Jr, MacCardle RC. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. Am J Med. 1962;33:811–28. Seyberth HW, Schlingmann KP. Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects. Pediatr Nephrol. 2011;26(10):1789–802. Konrad M, Vollmer M, Lemmink HH, VAN Den Heuvel LPWJ, Jeck N, Vargas- Poussou R, et al. Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. J Am Soc Nephrol. 2000;11(8):1449–59. Najafi M, Kordi-Tamandani DM, Behjati F, Sadeghi-Bojd S, Bakey Z, Karimiani EG, et al. Mimicry and well known genetic friends: molecular diagnosis in an Iranian cohort of suspected Bartter syndrome and proposition of an algorithm for clinical differential diagnosis. Orphanet J Rare Dis. 2019;14(1):41. Matsunoshita N, Nozu K, Yoshikane M, Kawaguchi A, Fujita N, Morisada N, et al. Congenital chloride Diarrhea needs to be distinguished from bartter and gitelman syndrome. J Hum Genet. 2018;63(8):887–92. Vaisbich MH, de Oliveira JC, Ferreira A, Hebbia Lobo Messa AC, Kok F. Congenital chloride Diarrhea in a bartter syndrome misdiagnosed Brazilian patient. J Rare Disord Diagn Ther. 2019;05(2):2–4. Matsunoshita N, Nozu K, Shono A, Nozu Y, Fu XJ, Morisada N, et al. Differential diagnosis of Bartter syndrome, Gitelman syndrome, and pseudo-Bartter/Gitelman syndrome based on clinical characteristics. Genet Med. 2016;18(2):180–8. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, et al. Gitelman’s variant of Bartter’s syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet. 1996;12(1):24–30. Nesbit MA, Hannan FM, Howles SA, Babinsky VN, Head RA, Cranston T, et al. Mutations affecting G-protein subunit alpha-11 in hypercalcemia and hypocalcemia. N Engl J Med. 2013;368(26):2476–86. Seyberth HW. An improved terminology and classification of Bartter-like syndromes. Nat Clin Pract Nephrol. 2008;4(10):560–7. Vaisbich MH, Fujimura MD, Koch VH. Bartter syndrome: benefits and side effects of long-term treatment. Pediatr Nephrol. 2004;19(8):858–63. Nascimento CLP, Garcia CL, Schvartsman BGS, Vaisbich MH. Treatment of Bartter syndrome. Unsolved issue. J Pediatr. 2014;90(5):512–7. Imbrici P, Conte D, Liantonio A. Paving the way for Bartter syndrome type 3 drug discovery: a hope from basic research. J Physiol. 2017;595(16):5403–4. Naslavsky MS, Scliar MO, Nunes K, Wang JYT, Yamamoto GL, Guio H, et al. Biased pathogenic assertions of loss of function variants challenge molecular diagnosis of admixed individuals. Am J Med Genet C Semin Med Genet. 2021;187(3):357–63. Pena SDJ, Santos FR, Tarazona-Santos E. Genetic admixture in Brazil. Am J Med Genet C Semin Med Genet. 2020;184(4):928–38. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629–37. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17(5):405–24. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Schlingmann KP, Konrad M, Jeck N, Waldegger P, Reinalter SC, Holder M, et al. Salt wasting and deafness resulting from mutations in two chloride channels. N Engl J Med. 2004;350(13):1314–9. Van Naarden K, Decoufle P. Relative and attributable risks for moderate to profound bilateral sensorineural hearing impairment associated with lower birth weight in children 3–10 years old. Pediatrics. 1999;104(4 Pt 1):905–10. Hoglund P, Auranen M, Socha J, Popinska K, Nazer H, Rajaram U, et al. Genetic background of congenital chloride Diarrhea in high- incidence populations: Finland, Poland, and Saudi arabia and Kuwait. Am J Hum Genet. 1998;63(3):760–8. Brochard K, Boyer O, Blanchard A, Loirat C, Niaudet P, Macher MA, et al. Phenotype–genotype correlation in antenatal and neonatal variants of Bartter syndrome. Nephrol Dial Transpl. 2009;24(5):1455–64. Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonça E, Stone R, et al. Mutations in the chloride channel gene, CLCNKB, cause Bartter’s syndrome type III. Nat Genet. 1997;17(2):171–8. Schurman SJ, Perlman SA, Sutphen R, Campos A, Garin EH, Cruz DN, et al. Genotype/phenotype observations in African Americans with Bartter syndrome. J Pediatr. 2001;139(1):105–10. Rodríguez Soriano J, Vallo A, Pérez de Nanclares G, Bilbao JR, Castaño L. A founder mutation in the CLCNKB gene causes Bartter syndrome type III in Spain. Pediatr Nephrol. 2005;20(7):891–6. Tajima T, Nawate M, Takahashi Y, Mizoguchi Y, Sugihara S, Yoshimoto M, et al. Molecular analysis of the CLCNKB gene in Japanese patients with classic Bartter Syndrome. Endocr J. 2006;53(5):647–52. Bettinelli A, Borsa N, Bellantuono R, Syrèn ML, Calabrese R, Edefonti A, et al. Patients with biallelic mutations in the chloride channel gene CLCNKB: long-term management and outcome. Am J Kidney Dis. 2007;49(1):91–8. Nozu K, Fu XJ, Nakanishi K, Yoshikawa N, Kaito H, Kanda K, et al. Molecular analysis of patients with type III bartter syndrome: picking up large heterozygous deletions with semiquantitative PCR. Pediatr Res. 2007;62(3):364–9. Nozu K, Iijima K, Kanda K, Nakanishi K, Yoshikawa N, Satomura K, et al. The pharmacological characteristics of molecular- based inherited salt-losing tubulopathies. J Clin Endocrinol Metab. 2010;95(12):E511–8. Urbanová M, Reiterová J, Stěkrová J, Lněnička P, Ryšavá R. DNA analysis of renal electrolyte transporter genes among patients suffering from Bartter and Gitelman syndromes: summary of mutation screening. Folia Biol. 2011;57(2):65–73. Lee BH, Cho HY, Lee H, Han KH, Kang HG, Ha IS, et al. Genetic basis of bartter syndrome in korea. Nephrol Dial Transpl. 2012;27(4):1516–21. García Castaño A, Pérez de Nanclares G, Madariaga L, Aguirre M, Madrid A, Nadal I, et al. Genetics of type III Bartter syndrome in Spain, proposed diagnostic algorithm. PLoS One. 2013 Sep 18;8(9):e74673. Lee JW, Lee J, Heo NJ, Cheong HI, Han JS. Mutations in SLC12A3 and CLCNKB and their correlation with clinical phenotype in patients with gitelman and gitelman-like syndrome. J Korean Med Sci. 2016;31(1):47–54. Han Y, Lin Y, Sun Q, Wang S, Gao Y, Shao L. Mutation spectrum of Chinese patients with Bartter syndrome. Oncotarget. 2017;8(60):101614–22. García Castaño A, Pérez de Nanclares G, Madariaga L, Aguirre M, Madrid Á, Chocrón S, et al. Poor phenotype-genotype association in a large series of patients with Type III Bartter syndrome. PLoS One. 2017;12(3):e0173581. Seys E, Andrini O, Keck M, Mansour-Hendili L, Courand PY, Simian C, et al. Clinical and genetic spectrum of bartter syndrome type 3. J Am Soc Nephrol. 2017;28(8):2540–52. Li Y, Wu C, Gu J, Li D, Yang Y. A novel mutation associated with Type III Bartter syndrome: a report of 5 cases. Mol Med Rep. 2019;20(1):65–72. Han Y, Cheng H, Shao S, Lang Y, Zhao X, Lin Y, et al. Thirteen novel CLCNKB variants and genotype/phenotype association study in 42 Chinese patients with Bartter syndrome type 3. Endocrine. 2020;68(1):192–202. Bokhari SRA, Mansur A. Bartter syndrome. In: StatPearls. Treasure island (FL). StatPearls Publishing LLC; 2018. Ji W, Foo JN, O’Roak BJ, Zhao H, Larson MG, Simon DB, et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet. 2008;40(5):592–9. Walsh PR, Tse Y, Ashton E, Iancu D, Jenkins L, Bienias M, et al. Clinical and diagnostic features of Bartter and Gitelman syndromes. Clin Kidney J. 2018;11(3):302–9. Al Shibli A, Narchi H. Bartter and Gitelman syndromes: spectrum of clinical manifestations caused by different mutations. World J Methodol. 2015;5(2):55–61. Konrad M, Nijenhuis T, Ariceta G, Bertholet-Thomas A, Calo LA, Capasso G, et al. Diagnosis and management of bartter syndrome: executive summary of the consensus and recommendations from the European rare kidney disease reference network working group for tubular disorders. Kidney Int. 2021;99(2):324–35. Chen H, Ma R, Du H, Liu J, Jin L. Early onset children’s Gitelman syndrome with severe hypokalaemia: a case report. BMC Pediatr. 2020;20(1):366. Palazzo V, Raglianti V, Landini S, Cirillo L, Errichiello C, Buti E, et al. Clinical and genetic characterization of patients with bartter and gitelman syndrome. Int J Mol Sci. 2022;23(10):5641. Article / Publication Details

First-Page Preview

Received: May 07, 2022
Accepted: November 28, 2022
Published online: March 07, 2023

Number of Print Pages: 18
Number of Figures: 3
Number of Tables: 3

ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)

For additional information: https://www.karger.com/NEF

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.